Medicare Enrolled

Dr. Billie Marek, MD

Medical Oncology · Mcallen, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
1901 S 2ND ST, Mcallen, TX 78503
9566875150
In practice since 2006 (19 years)
NPI: 1346282209 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Marek from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marek? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Marek

Dr. Billie Marek is a medical oncology specialist in Mcallen, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Marek performed 134,172 Medicare services across 3,028 unique beneficiaries.

Between the years covered by Open Payments, Dr. Marek received a total of $649 from 14 pharmaceutical and/or device companies across 21 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Marek is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 5% volume in TX $649 industry payments

Medicare Practice Summary

Medicare Utilization ↗
134,172
Medicare services
Top 5% in TX for medical oncology
3,028
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,062 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme) 38,250 $0 $5
Oxaliplatin chemotherapy injection 28,200 $0 $33
Pembrolizumab injection (Keytruda) 23,200 $43 $136
Contrast dye for imaging (iodine-based) 6,830 $0 $3
Epoetin alfa injection (Retacrit) for anemia 5,740 $6 $28
Darbepoetin injection (Aranesp) for anemia 5,175 $2 $20
Injection, atropine sulfate, 0.01 mg 3,200 $0 $1
Denosumab injection (Prolia/Xgeva) 2,820 $19 $67
Dexamethasone injection (steroid) 2,311 $0 $1
Immune globulin infusion (Octagam) 2,258 $33 $235
Injection, leucovorin calcium, per 50 mg 2,190 $3 $25
Injection, fluorouracil, 500 mg 1,846 $2 $13
Injection, irinotecan, 20 mg 1,305 $2 $210
Blood draw (venipuncture) 908 $8 $20
Complete blood count (CBC) with differential 870 $8 $36
Injection, granisetron hydrochloride, 100 mcg 790 $0 $24
Injection of additional new drug or substance into vein 684 $11 $108
Comprehensive metabolic blood panel 653 $10 $64
Office visit, established patient (30-39 min) 541 $90 $368
Anti-nausea injection (Aloxi/palonosetron) 530 $1 $114
Administration of chemotherapy into vein, 1 hour or less 522 $96 $707
Drug injection, under skin or into muscle 415 $10 $96
Injection, zoledronic acid, 1 mg 343 $6 $431
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 321 $22 $157
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg 316 $3 $373
Administration of chemotherapy into vein, each additional hour 286 $21 $161
Injection, iron dextran, 50 mg 266 $13 $43
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 234 $46 $313
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 233 $53 $211
Office visit, established patient (20-29 min) 222 $57 $250
Injection, magnesium sulfate, per 500 mg 220 $1 $6
Administration of additional new drug or substance into vein, 1 hour or less 192 $47 $344
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg 185 $345 $1,722
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l 184 $124 $500
Leuprolide acetate (for depot suspension), 7.5 mg 142 $136 $3,675
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour 130 $15 $100
Injection, diphenhydramine hcl, up to 50 mg 124 $1 $7
Irrigation of implanted venous access drug delivery device 119 $17 $114
Administration of additional new drug or substance into vein using push technique 116 $41 $289
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion 106 $15 $94
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle 99 $25 $145
Basic metabolic blood panel 93 $8 $49
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 93 $1 $17
CT scan of chest, without contrast 76 $41 $686
Ferritin level test (iron stores) 76 $13 $60
Iron level test 76 $6 $27
Iron binding capacity test 76 $8 $35
Ct scan of chest with contrast 73 $50 $821
PSA test (prostate cancer screening) 63 $18 $94
CT scan of abdomen and pelvis with contrast 57 $167 $1,067
Ct scan of abdomen and pelvis without contrast 56 $78 $560
Lactate dehydrogenase (enzyme) level 56 $6 $31
Reticulated (young) platelet measurement 45 $35 $143
Infusion, normal saline solution , 1000 cc 39 $2 $19
Drawing of blood for a medical problem 36 $60 $264
Nuclear medicine study from skull base to mid-thigh with ct scan 35 $1,109 $4,802
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 35 $91 $657
Office visit, established patient, complex (40-54 min) 31 $123 $496
Infusion into a vein for hydration, each additional hour 24 $10 $75
Ct scan of soft tissue of neck with contrast 20 $68 $658
New patient office visit (45-59 min) 13 $111 $565
Injection of drug or substance into vein 12 $26 $247
Ct scan of abdomen without contrast 11 $41 $658
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
31.0% high complexity
65.8% medium
3.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$649
Total received (2018-2024)
Avg $108/year across 6 years
Bottom 26% in TX for medical oncology
14
Companies
21
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$608 (93.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$41 (6.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$107
2023
$140
2022
$103
2021
$12
2019
$80
2018
$207

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$152
TESARO, Inc.
$122
Novartis Pharmaceuticals Corporation
$88
Celgene Corporation
$72
Gilead Sciences, Inc.
$43
Eisai Inc.
$26
E.R. Squibb & Sons, L.L.C.
$24
Medtronic, Inc.
$23
Sirtex Medical Inc
$21
Amgen Inc.
$20
Regeneron Healthcare Solutions, Inc.
$17
Janssen Biotech, Inc.
$15
PFIZER INC.
$13
Seattle Genetics, Inc.
$12
Top 3 companies account for 55.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · DARZALEX · INLYTA · KISQALI · Kyprolis · LIBTAYO · Lenvima · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · PROMACTA · Pomalyst · SCEMBLIX · SIR-Spheres Microspheres · VERZENIO · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $0 per 100 Medicare services performed
Looking for a medical oncology specialist in Mcallen?
Compare medical oncologists in the Mcallen area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
10
Per 100K population
1.1
County median income
$52,281
Nearest hospital
RIO GRANDE REGIONAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Marek is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Marek experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Marek performed 38,250 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Marek receive payments from pharmaceutical companies?
Yes. Dr. Marek received a total of $649 from 14 companies across 21 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marek's costs compare to other medical oncologists in Mcallen?
Dr. Marek's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marek) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →